FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/23/2026
Back to search
Official data from USPTO
HEALOME THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
07/23/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
02/27/2023
Registration date
12/30/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/30/2025
Last transaction
07/23/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
GB
Examiner
LINDEMYER, ANKHI MUKHERJEA
Law office
N50
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of two intersecting ovals made up of small aqua, black, and navy circles with the wording "HEALOME THERAPEUTICS" located below in black. White in the mark is background and not a feature of the mark.
Holders and representatives
Holders
Healome Therapeutics Ltd
Representatives
Nicole M. Meyer Dickinson Wright PLLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances and therapeutic pharmaceuticals for diseasestraumatic injuryperioperative careinflammation related to the eye; pharmaceutical preparationssubstances and treatments in the nature of eye dropssolutionsgelsfilms impregnated with preparations for the treatment of ocular and dermal conditionssterilized dressingssprayslubricantsointments used for treatment for ocular diseases and conditions; pharmaceutical preparationssubstances and treatments in the nature of eye dropssolutionsgelslubricantsointments used for treatment for ocular diseasesocular surface diseases and dry eye disease; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparationssubstances and treatments in the nature of solutionsgelsfilms impregnated with preparations for the treatment of ocular and dermal conditionssterilized dressingsspraysointments used for treatment for dermal diseases and conditions; pharmaceutical preparationssubstances and treatments in the nature of solutionsgelsfilms impregnated with preparations for the treatment of scarswounds and orthopaedic conditionsfor use in medical aesthetics treatmentssterilized dressingsspraysointments used for treatment for scar preventionwound healingmedical aesthetics and orthopaedic conditions; therapeutic preparations and substanceseye dropsocular lubricantssolutionsgelsfilms impregnated with preparations for the treatment of ocular diseasesocular conditionsocular surface diseases and dry eye diseasesterilized dressingssprayslubricantsointments for the treatment of ocular diseasesocular conditionsocular surface diseases and dry eye disease; gels for medical eye care; therapeutic gels for medical eye care; gel and liquid dropsspraysfilms for use as a delivery agent for drugs and for therapeutic pharmaceuticalssuspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditionssubstances in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gelssuspensionsliquids in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gelssuspensionsliquidslubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditions and diseases; tear film substitutes to provide lubricationprovide protectionsupport homeostasisfor use as a delivery agent for drugs and supplements in the treatment of ocular conditions; tear film substitutes to provide lubricationprovide protectionsupport homeostasisfor use as a delivery agent for drugs and supplements for the treatment of eye conditions and diseases; gelssuspensionsliquidslubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditionsglaucomacataractsamblyopiaage-related macular degeneration and diabetes-related retinopathy; gelssuspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticalsliquids for medical and therapeutic usefor treating eye diseasestreating traumatic eye injuryused in perioperative eye care; eye drops; eye ointment for medical use; medicated eye-washes; eye lotions for medical use; lubricating eye drops; medicated liquids for the treatment of ocular diseases and conditions; medicated ocular lubricants; tear film substitutes being pharmaceutical preparations for the treatment of ocular diseasesinjuries and conditions; tear substitutesartificial tears for ocular diseases and conditions; tear film substitutesbeing pharmaceutical preparations in the form of eye dropssolutionsgelssprayslubricantsointments and artificial tears for treatment of ocular diseases and conditions;
Class 42
Scientific and technological services and research and design relating theretoscientific research in the field of treatment of eye diseasesinjuries and conditionstreatment of dermal diseasesinjuries and conditionsin the field of biomaterials science; industrial scientific analysis and research services in the fields of eye care products and wound care products; product research and development services; scientific and technological services and research services relating theretoscientific research in the field of treatment of eye diseaseseye injuries and eye conditionstreatment of dermal diseasesinjuries and conditionsin the field of biomaterials science; scientific research services for medicalbiomedical and therapeutic purposes in the fields of ocular surface diseasesdry eye diseasesocular surface injurycorneal woundsglaucoma; medical and bioscience research services in the fields of ocular surface diseasesdry eye diseasesocular surface injurycorneal woundsglaucoma; biomedical research services; scientific research and development services relating to ocular diseasestreatment and conditions; research and development services relating to orthopaedics; scientific research and development services relating to dermatology; scientific research and development services relating to dermal applicationssuch as scar preventionwound healingmedical aesthetics; scientific research and development services relating to the treatment of diseases and conditions; scientific research services relating to the treatment of eye diseases and conditions; therapeutic research servicesscientific research in the field of eye diseases and eye injury; advisoryconsultancy and information services relating to all the aforesaid.
Publications
History of USPTO decisions and trademark events.
50 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/06/2026
FIMP
FINAL DISPOSITION PROCESSED
07/06/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/07/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/30/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/30/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
12/30/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/29/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/11/2025
PUBO
PUBLISHED FOR OPPOSITION
11/11/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/05/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/10/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
10/10/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/10/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
10/10/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/10/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/10/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/10/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/02/2025
GNRT
NON-FINAL ACTION E-MAILED
04/02/2025
CNRT
NON-FINAL ACTION WRITTEN
04/02/2025
DOCK
ASSIGNED TO EXAMINER
02/26/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
02/15/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/27/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/26/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/09/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/09/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
01/09/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
07/09/2024
GNFR
FINAL REFUSAL E-MAILED
07/09/2024
CNFR
FINAL REFUSAL WRITTEN
07/09/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/04/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/04/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/04/2024
RFNT
REFUSAL PROCESSED BY IB
01/03/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/13/2023
RFRR
REFUSAL PROCESSED BY MPU
12/13/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/05/2023
CNRT
NON-FINAL ACTION WRITTEN
12/04/2023
DOCK
ASSIGNED TO EXAMINER
11/28/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/25/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
10/25/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/25/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/25/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/25/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/25/2023
MAFR
APPLICATION FILING RECEIPT MAILED
09/05/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/01/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/31/2023
Continuous trademark protection
Get notified about every new filing that threatens HEALOME THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.